Her får du full pakke. 3xU. Upopulær, undervurdert og underanalysert.

Veldig bra informasjon i videoen. Legen og pasienten er veldig overbevisende i sine omtaler av løsningen.

Støtter dine 3 U'er helt her. Må si jeg synes at det er underlig at investorer står utenfor her! Dette er kjempepotensiale!

Nå er det slik at før Photocures utrolig oppsiktsvekkende resultater fra Fase 3 surveillance studie, før innvilgelse av refusjon i TURBT markedet og før godkjennelse i Surveillance markedet så har Photocure en markedsandel på 3 promille i USA. Dette i et marked hvor de bør bli markedsleder i et marked på 15 milliarder kroner. Bare i USA. Skulle ikke være noe å si på vekstmuligheter.

Resultatene som nå bygger seg opp blir overbevisende

Hadde vært morsom å vite om de som selger på dette nivået kjenner til hvilken posisjon PHO er i nå. Tipper det er en del gamle aksjonærer som har sluttet følge med forlenge siden. Men hvem vet?

nei, det kan en lure på . Sier ikke så mye listene heller på topp 50, men vi får vel bare følge med.

Nei nu for tiden bruker de mer penger en de tjener og det er vel ikke så enkelt att få ett positivt utslag på kursen med. Men vi vet jo att produktet er markedets beste per idag. Så skall vel salget ta seg opp betraktligt, nær pasienter og sykehus blir klar over att det er så. Det er jo i utgangspunktet ikke en dyr behandling og nær de nu refunder kostnaden for pasienten og, så må det bare bli en vinner. Vi vet att det snart kommer positive meldinger fra selskapet snart. Så får vi se hvor positive de blir..

Det satses for fult i USA, stadig nye jobb-annonser ute, Los Angeles, California
Princeton, New Jersey. - Seattle Area. -Chicago Area. -Miami/Fort Lauderdale Area

Det er ikke akkurat vaskekoner og vaktmestere dei søker etter.
Blir bra dette.

Photocure ASA

Job Title
Surgical Sales Executive
Company Name
Photocure ASA
Job Location
Miami/Fort Lauderdale Area
Desired Skills & Experience. Strong interpersonal skills; ability to handle "cold calls" as well as interactions with. Exceptional communication skills that include verbal, ...
New


Easy Apply

Job Title
Medical Science Liaison
Company Name
Photocure ASA
Job Location
Greater Chicago Area
PC literacy required; MSOffice skills (Outlook, Word, Excel, PowerPoint, e-mail, texting, use of mobile smart phone) Highly developed interpersonal skills...
4 days ago


Easy Apply

Job Title
Surgical Sales Executive
Company Name
Photocure ASA
Job Location
Greater Seattle Area
Desired Skills & Experience. Strong interpersonal skills; ability to handle "cold calls" as well as interactions with. Exceptional communication skills that include verbal, ...
6 days ago


Easy Apply

Job Title
Director, US Medical Affairs
Company Name
Photocure ASA
Job Location
Princeton, New Jersey
Excellent communication, presentation, and time management skills required; must be adaptable and able to work well within a team and relate effectively with people at all ...
2 weeks ago


Easy Apply

Job Title
Nat'l Health Systems & Reimbursement Mgr
Company Name
Photocure ASA
Job Location
Princeton, New Jersey
This position is responsible for delivering proactive communication of payer criteria, terms, policies and practices that relate to Photocure products and services. Excellent ...
2 weeks ago


Easy Apply

Job Title
Surgical Sales Executive
Company Name
Photocure ASA
Job Location
Los Angeles, California
Desired Skills & Experience. Strong interpersonal skills; ability to handle "cold calls" as well as interactions with. Exceptional communication skills that include verbal, ...
1 week ago


Easy Apply

Job Title
Surgical Sales Executive
Company Name
Photocure ASA
Job Location
Greater Boston Area
Desired Skills & Experience. Strong interpersonal skills; ability to handle "cold calls" as well as interactions with. Exceptional communication skills that include verbal, ...
6 days ago


Easy Apply

Never miss an opportunity.

Dette er årsaken til at USA urologer kaller Cysview a" Game Changer"

15/05-2017 08:30:00: (PHO) Positive data from Phase 3 US Blue Light Cystoscopy with Cysview® study presented at AUA 2017 meeting in Boston
- 21.5% of patients with recurrence of bladder cancer would
have been missed if BLFC with Cysview had not been used in the
surveillance setting, which is highly significant (p<0.0001)

- Photocure plans to file a supplemental NDA with FDA later
this year

Oslo, Norway, May 15th, 2017: Photocure ASA (Photocure, PHO:OSE),
today announced that new Phase 3 study results with Blue Light
Flexible Cystoscopy (BLFC(TM)) with Hexvix®/Cysview®* were presented
during a late-breaking plenary session at the American Urological
Association (AUA) Annual Meeting in Boston, Massachusetts on Sunday
May 14th. The study showed that BLFC with Cysview detected bladder
cancer recurrence in 21.5% of the patients undergoing surveillance
cystoscopy that otherwise would have been missed with white light
(WL) alone, which is highly significant (p<0.0001). Of note, the
study showed that nine out of twenty-six patients (34.6%) with flat,
more aggressive high grade lesions (carcinoma in situ; CIS) were
diagnosed using confirmatory Blue Light Cystoscopy with Cysview
alone and not WL (p<0.0001). The study also showed that there was no
increase in the rate of related adverse events after repeated
administration of Cysview in bladder cancer patients undergoing
cystoscopy examination.

The study was a prospective, open, comparative, within-patient
controlled study, included 304 patients with non-muscle invasive
bladder cancer (NMIBC) enrolled at 17 academic institutions in the
US. In the study BLFC with Cysview was used with the KARL STORZ D-
LIGHT C PDD Flexible Videoscope System.

"This study shows that BLFC can provide a significant advantage for
patients in terms of early detection of tumor recurrence which may
improve treatment and therefore lead to better outcomes," says one
of the lead investigators J. Stephen Jones, MD, president of
Cleveland Clinic Regional Hospitals and Family Health Centers.
"92.7% of the patients said it was worthwhile to undergo BLFC and
93.8% said that they would do it again. The results of the study
show that BLFC will play a significant role in outpatient management
of bladder cancer."

White light cystoscopy is the current standard of care for bladder
cancer surveillance. Multiple studies have demonstrated that Blue
Light Cystoscopy (BLC) with Cysview using a rigid endoscope in the
operating room improves detection of bladder cancer, with a
reduction in recurrence rates observed when compared to procedures
using white light. The objective of the Phase 3 study in the
surveillance setting was to determine if BLFC using a flexible
cystoscope in the office setting can improve detection of tumors
when compared to WL cystoscopy alone.

"As a result of the extensive follow up that NMIBC patients require
there are approximately 1.4 million surveillance cystoscopies with
flexible cystoscopes performed in the US annually. This market
represents a large potential opportunity for Photocure. We are very
pleased with these significant results for the detection of
recurrent bladder cancer. The patient related outcomes also
indicate that BLFC with Cysview adds considerable value to the
patient. With these positive efficacy and safety results we believe
we have fulfilled our post marketing commitments for the current
approved use and we are committed to working with the Food and Drug
Administration (FDA) to bring BLFC with Cysview to the physicians
and patients in the US." said Kjetil Hestdal, M.D., Ph.D., President
and CEO, Photocure ASA."

Click here for a link to the abstract: http://bit.ly/BLFCC-
LateBreaking.

In addition, on May12th at the AUA annual meeting, data from the
largest Bladder Cancer Registry Study in the US was presented at a
Poster session "Blue Light Cystoscopy for the diagnosis of
Urothelial Bladder Cancer: results from a prospective multicenter
registry". The results from 9 centers included 1325 lesions, from
517 procedures in 426 patients. The conclusion of the study was
that BLC significantly increased the detection of CIS and papillary
lesions over WLC alone and can result in upstaging and upgrading in
about 13% of patients, which can affect patient outcomes.

About Bladder Cancer
Bladder cancer is the fifth most commonly diagnosed cancer in the US
and is the fourth most common cancer found in men in the US(1, 2,
3). In 2016, it is estimated that 76,960 new cases of bladder cancer
will occur along with 16,390 deaths due to bladder cancer. Risk
factors for bladder cancer include advancing age, cigarette smoking,
occupational exposure to dyes, tar, rubber and solvent, chronic
bladder irritation and infections, and prior diagnosis of bladder
cancer. Bladder cancer is one of the most expensive cancers to
manage, accounting for approximately $3.7 billion in direct costs
each year(4, 5).

Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall(6). NMIBC is
still in the inner layer of cells. These cancers are the most common
(75%) of all BC cases and include the subtypes Ta, carcinoma in situ
(CIS) and T1 lesions. MIBC is when the cancer has grown into deeper
layers of the bladder wall. These cancers, including subtypes T2, T3
and T4, are more likely to spread and are harder to treat(7).

About Hexvix®/Cysview®
Hexvix® is a drug that is taken up selectively by cancer cells in
the bladder making them glow bright pink during Blue Light
Cystoscopy (BLC). BLC with Hexvix® improves the detection of tumors
and leads to more complete resection, less residual tumors and
better management decisions (US)/ reduced risk of recurrence and
progression (Nordic).

Hexvix® is the tradename in Europe, Cysview® in the US and Canada.
Hexvix® is marketed and sold by Photocure in the Nordic countries
and in the US with the trade name Cysview®. Photocure has a
strategic partnership with Ipsen for the commercialization of
Hexvix® in Europe, excluding the Nordic region. Please refer to
https://www.photocure.com/Partnering-with-Photocure/Our-partners for
further information on our commercial partners.

About KARL STORZ Endoscopy-America, Inc.
KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ
GmbH & Co. KG, an international leader for more than 70 years in
reusable endoscope technology, encompassing all endoscopic
specialties. Based in Tuttlingen, Germany, KARL STORZ GmbH & Co. KG
is a family-owned company that designs, engineers, manufactures, and
markets all its products with an emphasis on visionary design,
precision craftsmanship and clinical effectiveness. For more
information, call (800) 421-0837 or visit the company's website at
www.karlstorz.com.

About Photocure ASA
Photocure, headquartered in Oslo Norway, is a specialty
pharmaceutical company focusing on urology. Based on its unique
proprietary Photocure Technology® platform, Photocure is committed
to developing and commercializing highly selective and minimally
invasive solutions to improve health outcomes for patients
worldwide. The company is listed on the Oslo Stock Exchange (OSE:
PHO). Information about Photocure is available at www.photocure.com.

For more information, please contact:
Kjetil Hestdal
President and CEO, Photocure ASA
Tel: +47 913 19 535
Email: kh@photocure.no

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: ed@photocure.no

Emily Dell
Media contact
MCS Healthcare public relations
Tel: +1 732 589-0757

Stephen Jones, MD, president of
Cleveland Clinic Regional Hospitals and Family Health Centers.
"92.7% of the patients said it was worthwhile to undergo BLFC and
93.8% said that they would do it again. The results of the study
show that BLFC will play a significant role in outpatient management
of bladder cancer."
Jeg gjentar:
The results of the study
show that BLFC will play a significant role in outpatient management
of bladder cancer."

Som betyr at Cysview vil få en betydelig rolle i USA sitt surveillance marked på 12 milliarder per år.

Hva tror dere kursen er sommer 2018 ?

Mellom 20 og 200.